news

11 April 2024

IAMA Therapeutics Appoints Federico Bolognani as Chief Medical Officer

GENOA, Italy, April 11, 2024 — IAMA Therapeutics today announced the appointment of Federico Bolognani, MD, PhD, as Chief Medical Officer (CMO). Bringing extensive expertise in […]
19 February 2024

IAMA Therapeutics Successfully Dosed the First Two Cohorts in First-in-Human Clinical Trial

GENOA, Italy, February 19, 2024 — IAMA Therapeutics has successfully dosed the first two cohorts of subjects and has started dosing the third one in the […]
23 January 2024

IAMA Therapeutics Announces First Subject Dosed in Phase 1 Study of IAMA-6 for the Treatment of Autism and Epilepsy

GENOA, Italy, January 23, 2024 — IAMA Therapeutics, a pharmaceutical company focused on the discovery, development, and commercialization of novel medicines for children affected by brain […]
20 December 2023

IAMA Therapeutics Announces Approval of Clinical Trial Application (CTA) by the Italian Medicines Agency (AIFA) to Initiate a Phase 1 Study of IAMA-6 for the Treatment of Autism and Epilepsy

GENOA, Italy, December 20, 2023 — IAMA Therapeutics, a pharmaceutical company focused on the discovery, development, and commercialization of novel medicines for children affected by brain […]
1 December 2023

IAMA Therapeutics to Present New Preclinical Data at Upcoming American Epilepsy Society 2023 Annual Meeting

Study results support the potential for IAMA-6 as a disease-modifying therapy for drug-resistant epilepsies GENOA, Italy, December 1, 2023 — IAMA Therapeutics, a pharmaceutical company focused […]
2 October 2023

IAMA Therapeutics Announces Multi-Phase, Strategic Provider Agreement with Evotec

GENOA, Italy, October 02, 2023 — IAMA Therapeutics, a pharmaceutical company focused on the discovery, development, and commercialization of novel medicines for children affected by brain […]
13 September 2023

IAMA Therapeutics to Present at Sachs Associates 23rd Annual Biotech in Europe Forum

GENOA, Italy, September 13, 2023 — IAMA Therapeutics, a pharmaceutical company focused on the discovery, development, and commercialization of novel medicines for children affected by brain […]
10 July 2023

IAMA Therapeutics Announces Sponsored Research Agreement with The Sapienza University of Rome, Italy

GENOA, Italy, July 10, 2023 — IAMA Therapeutics, a pharmaceutical company focused on the discovery, development, and commercialization of novel medicines for children affected by brain […]
1 June 2023

IAMA Therapeutics to Present at Upcoming BIO International Convention

GENOA, Italy, June 1, 2023 – IAMA Therapeutics, a preclinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel medicines to make a difference in […]
31 May 2023

Business Wire – 31/05/2023

IAMA Therapeutics Announces Addition of Paul Frohna M.D., Ph.D., PharmD, Pierandrea Muglia, M.D. and Elaine Wirrell, M.D., to Scientific Advisory Board
13 January 2023

Business Wire – 12/01/2023

IAMA Therapeutics and Psychogenics Sign a Preclinical Study Agreement for Dravet Syndrome
26 July 2022

Business Wire – 27/07/22

IAMA Therapeutics Announces Initiation of Preclinical Development Studies in Drug-resistant Epilepsy Under a Service Agreement with Psychogenics
29 June 2022

Business Wire – 29/06/22

IAMA Therapeutics to Present Preclinical Data of Selective NKCC1-Inhibitors at the International Neuroscience Conference FENS Forum 2022
24 May 2022

Business Wire – 24/05/22

IAMA Therapeutics Announces Oral Presentation at the XXVII EFMC International Symposium on Medicinal Chemistry
31 March 2022

Business Wire – 31/03/22

IAMA Therapeutics Announces Formation of Scientific Advisory Board
11 February 2022

Business Wire – 29/03/22

IAMA Therapeutics Partners with the Italian Institute of Technology to Embark on Landmark Research on Neuroscience Drug Discovery